Form 4: BioMarin Director Bienaime Reports Stock Transaction
SEC Form 4 Filing
Director Jean Jacques Bienaime reports disposition of BioMarin Pharmaceutical Inc. shares to cover tax obligations.
Summary
- On May 20, 2024, Jean Jacques Bienaime, a director at BioMarin Pharmaceutical Inc., reported a transaction involving common stock.
- The transaction involved the disposition of 1,202 shares at a price of $77.05.
- Following the transaction, Bienaime directly owns 473,792 shares of common stock.
- Bienaime also indirectly owns 247,333 shares through the Jean-Jacques Bienaime Family Trust and 200 shares as UTMA custodian for two children.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a stock transaction by a company director, which has a neutral sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor the actions of those with privileged information.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on stakeholders as it is a relatively small number of shares being sold by a director.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of the stock transaction |
| 05/21/2024 | Date of signature for the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.